{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-398015","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-09-22T20:41:04+00:00","discovered_at":"2026-09-22T20:42:00.588848+00:00","generated_at":"2026-09-22T20:42:11.264665+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Halozyme completes $1.5B 1.50% convertible notes due 2033; repurchases existing notes","bullets":["Issued $1.5B aggregate 1.50% Convertible Senior Notes due 2033; net proceeds ~$1,471.1M.","Repurchasing $151.7M of 0.25% 2027 Notes and $220M of 1.00% 2028 Notes for ~$217M and $435.5M incl. interest.","Spent $187.5M on capped call transactions; cap price initially $208.39/share (~90% premium).","Initial conversion price ~$139.84/share (7.1509 shares per $1,000 principal).","Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-398015","json":"https://secwatch.observer/filing/0001193125-26-398015.json","markdown":"https://secwatch.observer/filing/0001193125-26-398015.md","text":"https://secwatch.observer/filing/0001193125-26-398015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/0001193125-26-398015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/d148460d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-22T20:42:11.264665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}